Search Page

1

Cite

Share

The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation.

Conner KP, Devanaboyina SC, Thomas VA, Rock DA. Conner KP, et al. Among authors: rock da. Pharmacol Ther. 2020 Aug;212:107574. doi: 10.1016/j.pharmthera.2020.107574. Epub 2020 May 17. Pharmacol Ther. 2020. PMID: 32433985 Review.

Cite

Share

2

Cite

Share

Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.

Barr JT, Wang Z, Min X, Wienkers HJ, Rock BM, Rock DA, Wienkers LC. Barr JT, et al. Among authors: rock da. Drug Metab Dispos. 2020 Jun;48(6):508-514. doi: 10.1124/dmd.119.089813. Epub 2020 Mar 19. Drug Metab Dispos. 2020. PMID: 32193357

Cite

Share

3

Cite

Share

Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins.

Pearson JT, Rock DA. Pearson JT, et al. Among authors: rock da. Bioanalysis. 2015 Dec;7(23):3035-51. doi: 10.4155/bio.15.217. Epub 2015 Nov 30. Bioanalysis. 2015. PMID: 26617274 Review.

Cite

Share

4

Cite

Share

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.

Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li CM, Bücklein VL, Krupka C, Boyle MC, Koppikar P, Haubner S, Wahl J, Dahlhoff C, Raum T, Rardin MJ, Sastri C, Rock DA, von Bergwelt-Baildon M, Frank B, Metzeler KH, Case R, Friedrich M, Balazs M, Spiekermann K, Coxon A, Subklewe M, Arvedson T. Brauchle B, et al. Among authors: rock da. Mol Cancer Ther. 2020 Sep;19(9):1875-1888. doi: 10.1158/1535-7163.MCT-19-1093. Epub 2020 Jun 9. Mol Cancer Ther. 2020. PMID: 32518207 Free article.

Cite

Share

5

Cite

Share

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.

Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, Yang JJ, Barfield M, Xiao G, Escandon E, Wang W, Rock DA, Chemuturi NV, Moore DJ. Kraynov E, et al. Among authors: rock da. Drug Metab Dispos. 2016 May;44(5):617-23. doi: 10.1124/dmd.115.068049. Epub 2015 Dec 15. Drug Metab Dispos. 2016. PMID: 26669328 Review.

Cite

Share

6

Cite

Share

Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues.

Conner KP, Pastuskovas CV, Soto M, Thomas VA, Wagner M, Rock DA. Conner KP, et al. Among authors: rock da. MAbs. 2020 Jan-Dec;12(1):1746520. doi: 10.1080/19420862.2020.1746520. MAbs. 2020. PMID: 32310023 Free PMC article.

Cite

Share

7

Cite

Share

Reagent-free LC-MS/MS-based pharmacokinetic quantification of polyhistidine-tagged therapeutic proteins.

Shi J, Wong JM, Ma J, Dickerson T, Hall C, Rock DA, Carlson TJ. Shi J, et al. Among authors: rock da. Bioanalysis. 2017 Feb;9(3):251-264. doi: 10.4155/bio-2016-0126. Epub 2017 Jan 18. Bioanalysis. 2017. PMID: 28097886

Cite

Share

8

Cite

Share

"Target-Site" Drug Metabolism and Transport.

Foti RS, Tyndale RF, Garcia KL, Sweet DH, Nagar S, Sharan S, Rock DA. Foti RS, et al. Among authors: rock da. Drug Metab Dispos. 2015 Aug;43(8):1156-68. doi: 10.1124/dmd.115.064576. Epub 2015 May 18. Drug Metab Dispos. 2015. PMID: 25986849

Cite

Share

9

Cite

Share

A quantitative method for detection of circulating fms related tyrosine kinase 3 (FLT-3) in acute myeloid leukemia (AML) patients.

Cook KD, Finger EC, Santos CD, Rock DA. Cook KD, et al. Among authors: rock da. J Immunol Methods. 2019 Jul;470:55-58. doi: 10.1016/j.jim.2019.04.010. Epub 2019 Apr 26. J Immunol Methods. 2019. PMID: 31034878

Cite

Share

10

Cite

Share

Characterization of the active site properties of CYP4F12.

Eksterowicz J, Rock DA, Rock BM, Wienkers LC, Foti RS. Eksterowicz J, et al. Among authors: rock da. Drug Metab Dispos. 2014 Oct;42(10):1698-707. doi: 10.1124/dmd.114.059626. Epub 2014 Jul 29. Drug Metab Dispos. 2014. PMID: 25074871

Cite

Share